Navigation Links
Dynavax Reports Progress in Lupus Program With Inhibitor of TLR7 and TLR9
Date:11/26/2007

lliance for Lupus Research awarded to Dynavax a $500,000 grant to explore new treatment approaches for systemic lupus erythematosus based on the company's novel IRS technology. The grant was the first time ALR had provided funding to a private company.

About Dynavax

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative TLR9 agonist-based products to treat and prevent infectious diseases, allergies, cancer, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our TLR9 agonists are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Our product candidates include: HEPLISAVTM, a hepatitis B vaccine in Phase 3 partnered with Merck & Co. Inc.; TOLAMBATM, a ragweed allergy immunotherapy in Phase 2; a therapy for non-Hodgkin's lymphoma (NHL) in Phase 2 and for metastatic colorectal cancer in Phase 1; and a therapy for hepatitis B also in Phase 1. Our preclinical asthma and COPD program is partnered with AstraZeneca. The National Institutes of Health (NIH) partially funds our preclinical work on a vaccine for influenza. Symphony Dynamo, Inc. (SDI) funds our colorectal cancer trials and our preclinical hepatitis C therapeutic program, and Deerfield Management has committed funding for our allergy programs. While Deerfield, NIH and SDI provide program support, Dynavax has retained rights to seek strategic partners for future development and commercialization. For more information, please visit http://www.dynavax.com.

This press release contains forward-looking statements that are subject to a number of risks and uncertainties, including statements about the potential for our IRS as an approach for the treatment of lupus and multiple autoimmune diseases. Actual results
'/>"/>

SOURCE Dynavax Technologies Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dynavax Issued Landmark Patent Covering Second-Generation TLR9 Agonists
2. Dynavax to Present at UBS 2007 Global Life Sciences Conference
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. QMed, Inc. Reports July Medicare SNP Enrollments
5. Phlo Affiliate Reports Expanded Coverage to Oregon Border
6. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
7. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... 2014 The Asian Automatic patient billing ... analysis and forecast of revenue. The Automatic patient billing ... $463.9 million by 2018, at a developing CAGR of ... TOC of the Asian Automatic patient billing market, to ... also provides a glimpse of the segmentation of this ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 The report ... Market Share, Trade, Prices, Geography Trend and Forecast (2011 ... sales category, and geography and studies the major market ... North America, Europe, and Asia. , The global chocolate ... 2010.to $98.3 billion in 2016 at an estimated CAGR ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 The ... Defense, & Homeland Security), Technology, Payload, Type & ... and segments the global unmanned ground vehicle market ... and forecasting of market sizes. The report also ... and opportunities impacting it along with the adoption ...
(Date:10/18/2014)... The “Human Insulin Market- by Product Type, ... Human Insulin (Rapid Acting, Long Acting, Premixed)], by ... - Forecast to 2018” provides a detailed overview ... market trends, and strategies impacting the global human ... of the revenue and share analysis. , The ...
Breaking Biology Technology:The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 2Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 3Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 4Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 5Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 2Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 3Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 5
... the world over are striving to develop organic solar cells ... that could be widely used to generate electricity. But ... form the proper structure at the nanoscale (tinier than 2-millionths ... to electricity. The goal is to develop cells made from ...
... , , , , ... Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on ... 30, 2009, and provided a corporate update. , , ... we reported promising Phase 2 picoplatin data from our colorectal and ...
... , LYNBROOK, N.Y., Aug. 4 ... biopharmaceutical company developing first in class collagenase-based products, announced today ... audio webcast at 4:30 p.m. ET on Wednesday, August 12, ... corporate highlights. , , To participate ...
Cached Biology Technology:Plastics that convert light to electricity could have a big impact 2Plastics that convert light to electricity could have a big impact 3Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update 2Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update 3Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update 4Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update 5Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update 6Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update 7Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update 8BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2009 Financial Results on August 12, 2009 2
(Date:10/15/2014)... N.Y. , Oct. 15, 2014 ... solutions for home and community-based care, today announced ... of implementing Sandata,s Santrax® Electronic Visit Verification™ Solution ... Services is a home health company founded in ... Texas . The study ...
(Date:10/15/2014)... The Ebola virus is spreading rapidly and to an ... experienced in the past and the virus shows a ... been recorded before. For this reason, the German National ... of Science and Engineering, and the Union of the ... statement on the Ebola epidemic today. , In the ...
(Date:10/15/2014)... , Oct. 15, 2014   Neurotechnology ... today announced the availability of the VeriLook ... Surveillance 3.0 provides real-time biometric face identification using ... digital surveillance cameras. The new version not only ... differentiates people from objects while they are moving ...
Breaking Biology News(10 mins):Sandata Announces Case Study with Quality Care Services, Inc. 2Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3
... On June 28-30, 2011 , the New York ... from a wide range of subspecialties, in addition to ... advances in our understanding of the clinical features, management, ... multiple organ systems and affecting children and young adults. ...
... Amsterdam, June 22, 2011 Elsevier, a world-leading provider ... in association with the Australian Society for Parasitology, is ... International Journal for Parasitology: Drugs and Drug Resistance ... affiliated with the leading parasitology journal, International Journal ...
... A new technique developed at Rensselaer Polytechnic Institute allows ... nanoscale bone samples. Along with adding important ... opens up an entirely new proteomics-based approach to analyzing ... forensic study of human skeletons. "We,re able to ...
Cached Biology News:New York Academy of Sciences hosts a conference on rare disease Shwachman-Diamond Syndrome 2Elsevier launches International Journal for Parasitology: Drugs and Drug Resistance 2New technique yields troves of information from nanoscale bone samples 2New technique yields troves of information from nanoscale bone samples 3